Stocktoria
LEXICON PHARMACEUTICALS, INC. LXRX
LEXICON PHARMACEUTICALS, INC. (LXRX) earns a Piotroski F-score of 3/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $49.8M at a -101.1% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -1.2 — elevated (above the −1.78 line — aggressive-accounting signals worth a closer look) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| LXRX | LEXICON PHARMACEUTICALS, INC. | 3/9 | — | — | +60.2% |
| GOSS | Gossamer Bio, Inc. | — | — | — | -57.7% |
| OCUL | OCULAR THERAPEUTIX, INC | 3/9 | 3.49 | — | -18.5% |
| XOMA | XOMA Royalty Corp | 5/9 | -11.82 | 23.3 | +83.1% |
| PTGX | Protagonist Therapeutics, Inc | 4/9 | 13.41 | — | -89.4% |
| SEPN | Septerna, Inc. | 4/9 | 3.75 | — | — |
| QTTB | Q32 Bio Inc. | 3/9 | -2.11 | 7.5 | — |
About LEXICON PHARMACEUTICALS, INC.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, CKD, and other cardiovascular risk factors. In addition, the company develops LX9851, an orally-delivered small molecule drug candidate for the treatment of obesity and associated cardiometabolic disorders, and pilavapadin (LX9211), an orally-delivered small molecule drug candidate for the treatment of neuropathic pain. It has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
FAQ
Is LXRX financially healthy?
LEXICON PHARMACEUTICALS, INC.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak).
Does LXRX pay a dividend?
No, LEXICON PHARMACEUTICALS, INC. does not currently pay a dividend.
How profitable is LXRX?
In FY2025, LEXICON PHARMACEUTICALS, INC. had a net margin of -101.1% and a return on equity of -46.8%.
What is the analyst price target for LXRX?
The average Wall-Street price target for LEXICON PHARMACEUTICALS, INC. is $3.77, about 60.4% above the recent price, from 5 analysts (consensus: buy).
Is LXRX a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on LEXICON PHARMACEUTICALS, INC.: a Piotroski F-score of 3/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.